REMARKS/ARGUMENTS

In an Office Action dated November 29, 2005, the Examiner required that the claims be restricted to one of the following inventions:

- I. Claims 1-10, drawn to a method for treating tumors or increasing the uptake of cytotoxic agents into a tumor.
- II. Claims 11-14, drawn to a therapeutic composition comprising a PDGF aptamer and a cytotoxic agent.

Applicant hereby elects Invention I (claims 1-10) drawn to a method for treating tumors or increasing the uptake of cytotoxic agents into a tumor, without traverse. Claims 11-14 have been canceled.

This constitutes a request for any needed extension of time and an authorization to charge all fees therefore to deposit account No. 19-5117, if not otherwise specifically requested. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to be charged to deposit account No. 19-5117.

Respectfully submitted,

Date: 1) (Cember 8, 2005

osemary Kellogg, #39,726

Swanson & Bratschun, L.L.C. 1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

Telephone:

(303) 268-0066

Facsimile:

(303) 268-0065

S:\ClientFolders\Gilead (formerly NeXstar)\Nex90\C\response to restriction requirement2.doc